was rarely reported previously. Even new antibiotics have joined the resistance club at an alarming rate. For example, the resistance rates of H. pylori to levofloxacin (10.3%, 24.0% and 32.5%) have increased from 2000 to 2009 .
4) It is accepted that the overall efficacy of the standard triple treatment has markedly declined mainly due to antibiotic resistance; in some areas it has reached alarming levels (60-80%). However, it has been recommended that treatment should achieve an eradication rate of >80% (3). 5) Sequential therapy is a promising therapy (9-11), but the effects still remain controversial in some countries (12-15), thus further trials are needed in other European countries and North America. As far as we know, one potential mechanism by which sequential therapy achieves superior eradication rates is that the organism is exposed to all of the key antibiotics together we have currently available. If it fails one day, what should we do?
6) The past experience seems to indicated that it is not as efficacious anymore as previous expectations, and actually, the choice of initial therapy is in a state of flux. Therefore a variety of methods must be used to achieve successful eradication. It is the same as in other infectious diseases, theoretically, the destruction should be directly targeted rather than by merely using a "hit or miss" process. Susceptibility testing is still the gold standard to separate susceptible and resistance strains, although it still needs technical improvement (16). 7) A new method gives us new hope. Molecular methods of detection of specific changes in the organisms' genome are alternative approaches to detection of resistance and in theory allow a more rapid detection of resistance as well as detection of resistance using stool or biopsy specimens (17).
For the above-mentioned reasons, individual treatment should be advocated. For example, macrolide susceptibility testing by culture or molecular methods is now necessary before prescribing clarithromycin, due to the high prevalence and big gap of this resistance (18).
Anyway, the picture is still far from clear, clinicians need to carefully consider the currently available options for the treatment of H. pylori. Susceptibility testing should be taken into account, which is the most rational option but it is currently not used widely enough, particularly in the high gastric cancer risk population in high antibiotic resistance regions. And more well-designed, double-blind, and wide ranging geographical RCTs are still needed.
My Commentary can only serve as an introduction to the complex issue of H. pylori treatment. It may also, provide
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